Effect of novel anticoagulants on traditional laboratory assessments of coagulation in humans
| . | ECT . | Xa inhibition . | TCT . | PT . | aPTT . |
|---|---|---|---|---|---|
| Dabigatran 200 mg TID | 5.2* | No effect | 27* | Not reported | 2.3* |
| Rivaroxaban 30 mg BID | No effect | 68% | No effect | 2.6* | 1.8* |
| Apixaban 25 mg BID | No effect | Not reported | Not reported | Not reported | 1.2* |
| . | ECT . | Xa inhibition . | TCT . | PT . | aPTT . |
|---|---|---|---|---|---|
| Dabigatran 200 mg TID | 5.2* | No effect | 27* | Not reported | 2.3* |
| Rivaroxaban 30 mg BID | No effect | 68% | No effect | 2.6* | 1.8* |
| Apixaban 25 mg BID | No effect | Not reported | Not reported | Not reported | 1.2* |
Modified from Eriksson et al.24
ECT indicates ecarin clotting time; TCT, thrombin clotting time; PT, prothrombin time; aPTT, activated partial thromboplastin time; TID, three times daily; and BID, twice daily.
Estimated fold increase from baseline at peak levels.